Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A malignant serous cystic epithelial neoplasm arising from the ovary. It is characterized by the presence of glandular, papillary, or solid structures. Psammoma bodies may be present. In well differentiated cases the malignant epithelial cells resemble the cells of fallopian tube epithelium. In poorly differentiated cases the malignant epithelial cells show anaplastic features.
Biomarker and diagnostic research for ovarian serous cystadenocarcinoma has been reported in the published literature.
3 clinical trials registered. Interventions under study include drug therapy, other interventions, and biologic therapy. Pipeline includes 2 PHASE2, 1 PHASE1. Research is primarily sponsored by academic and government institutions.
34 publications have been identified in PubMed for ovarian serous cystadenocarcinoma. Research spans Diagnostic / Biomarker (41%), Basic Science / Preclinical (38%), and Case Report / Case Series (9%).
Research Type | Count | % of Total |
|---|---|---|
Testing and diagnosis research | 14 |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 6:52 AM UTC
Laboratory research | 13 | 38% |
Patient case studies | 3 | 9% |
New treatment approaches | 3 | 9% |
Other research | 1 | 3% |
Hussein A (2026). [PMID: 41971961](https://pubmed.ncbi.nlm.nih.gov/41971961/). *Radiol Case Rep*. [Case Report / Case Series]
Bahmad HF (2026). [PMID: 41915930](https://pubmed.ncbi.nlm.nih.gov/41915930/). *Int J Gynecol Pathol*. [Diagnostic / Biomarker]
Kołat D (2026). [PMID: 41828532](https://pubmed.ncbi.nlm.nih.gov/41828532/). *Int J Mol Sci*. [Basic Science / Preclinical]
Gui J (2026). [PMID: 41587322](https://pubmed.ncbi.nlm.nih.gov/41587322/). *Brief Bioinform*. [Basic Science / Preclinical]
Cho SY (2026). [PMID: 41530649](https://pubmed.ncbi.nlm.nih.gov/41530649/). *Reprod Sci*. [Gene Therapy / Novel Therapeutics]
Pedersen S (2025). [PMID: 40330446](https://pubmed.ncbi.nlm.nih.gov/40330446/). *Contemp Oncol (Pozn)*. [Diagnostic / Biomarker]
Yay F (2025). [PMID: 41082091](https://pubmed.ncbi.nlm.nih.gov/41082091/). *Reprod Sci*. [Diagnostic / Biomarker]
Karaman E (2025). [PMID: 40001977](https://pubmed.ncbi.nlm.nih.gov/40001977/). *Biology (Basel)*. [Diagnostic / Biomarker]
Ling L (2025). [PMID: 40382612](https://pubmed.ncbi.nlm.nih.gov/40382612/). *BMC Womens Health*. [Diagnostic / Biomarker]
DU NN (2025). [PMID: 40326068](https://pubmed.ncbi.nlm.nih.gov/40326068/). *Sheng Li Xue Bao*. [Basic Science / Preclinical]